InspireMD (NSPR) Q3 2026 Earnings Call Transcript
InspireMD (NSPR) announced FDA approval for its CGuard Prime TransCarotid Stent System, expanding U.S. market access by 40,000 annual procedures. Q3 2026 international revenue grew 9% YoY to $2.2M. The company plans commercial execution and cost alignment, with a 20% workforce reduction. FDA submission for the CGuard Prime 135 CAS delivery system is expected by year-end.
How this was made

The 30-second read
Why it matters
The approval expands the addressable market by ~40,000 procedures annually, potentially doubling revenue opportunity and supporting a strategic shift to commercial execution.
Market read
First‑time FDA approval for a micro‑cap med‑tech firm is a high‑impact catalyst likely to move the stock and influence sector peers.
What to watch
Potential supply chain constraints and the pending recall of the prior delivery system may limit near‑term sales
Background
InspireMD announced FDA clearance for its next‑generation CGuard Prime TransCarotid Stent, marking a return to the U.S. market after a prior recall.
Ticker impact
FDA approval of the CGuard Prime TransCarotid Stent System enables U.S. market entry and expands addressable procedures.
likely upward pressure as investors price in new U.S. sales potential
Regulatory clearance is a material catalyst for a micro‑cap medical device firm, historically moving the stock sharply on first‑time approvals.
Market effects
strengthens outlook for carotid intervention devices and may benefit peers with similar pipelines
U.S. market re‑entry could boost domestic medical‑device sector sentiment
shows continued pipeline success for U.S. regulatory approvals in the global med‑tech space
Counterpoint
If commercial rollout stalls or reimbursement issues arise, the stock could face disappointment despite approval
Key entities
- CompanyInspireMD
Medical device maker focused on carotid revascularization
- ExecutiveKathy Kennedy
Senior Vice President of Global Sales and Marketing

